RE:RE:RE:RE:RE:RE:Soleus IF and it is s big IF the clinical results come out good then you should rejoice.
If the redults are not good you should also be pleased that there is a safety net not to default on the Marathon debt
You need to understand that the Company was not aware of positive results at the time of the Financing
SPCEO1 wrote: They already should have six week results on the first patient and could potentially have even more than that if they signed up one or two more patients pretty quickly after the first. They can talk about any results anytime they want to as these are open label trials but since they are not in a money raising mode at the moment, I think the chances of them sharing news early is small. The next news expected is they have dosed the sixth patient. Maybe we will get some news on results on the first six patients sometime in the middle of the first quarter of 2024. If the results are not that impressive, then I suspect the chances they continue with the trial into its next phase are minimal.
I suspect there is a decent chance the results will be good enough for them to move forward given the changes to the trial. The limiting factor is potential randomness of results with just six patients.
If the results are good, that opens up a lot of possibilities for THTX. If the results are bad, it is back to trying to keep costs low and turn a profit with the current two approved drugs. Either outcome should lead to a higher share price but good TH-1902 results opens up the chances of a big move higher in the share price.
It would also greatly irritate all legacy shareholders even further because it would highlight the seeming absurdity of giving half the company away at a ridiculous price in the most recent offering.
bigkagan wrote: Probably some news soon about the cancer trial. When the patient dozing is done the first results will start coming in, similar to MDNA trial when they reported the early results and the stock almost doubled